Multiple Sclerosis News Today

FDA gives tentative approval to generic Siponimod tablets for MS

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...
Monthly Prescribing Reference

Briumvi Approved for Relapsing Forms of Multiple Sclerosis

The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...
Healio

Evobrutinib nonsuperior to teriflunomide for relapsing forms of MS

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...
Nasdaq

TG Therapeutics Highlights BRIUMVI® Data in Patients with Relapsing Forms of Multiple Sclerosis at CMSC 2025 Annual Meeting

TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...
The American Journal of Managed Care

ZEPOSIA® (ozanimod), a Sphingosine 1-Phosphate Receptor Modulator for Relapsing Forms of Multiple Sclerosis

This publication was sponsored and written in partnership with Bristol Myers Squibb. This Clinical Brief provides key information on sphingosine 1-phosphate receptor modulators for relapsing forms of ...
Nasdaq

Sandoz: FDA Okays Biosimilar Tyruko For Relapsing Forms Of Multiple Sclerosis

(RTTNews) - Sandoz said that the U.S. Food and Drug Administration approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat all indications ...
Monthly Prescribing Reference

Ublituximab Under Review for Relapsing Forms of Multiple Sclerosis

Credit: Getty Images. Ublituximab is an investigational glycoengineered monoclonal antibody that targets CD20. The Food and Drug Administration (FDA) has accepted the Biologics License Application for ...
Business Wire

Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis

–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...
Healio

FDA approves Tysabri biosimilar Tyruko for relapsing forms of multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...
Business Insider

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® ...
Business Wire

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase 3 ...
The American Journal of Managed Care

Ublituximab Approved for Relapsing Forms of Multiple Sclerosis

Ublituximab-xiiy, developed by TG Therapeutics, will be sold under the name Briumvi. The FDA recently approved ublituximab-xiiy for the treatment of relapsing forms of multiple sclerosis (RMS), to ...